Search Result

Results for "

Haemophilus

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aminoacyl-tRNA Synthetase (4) Antibiotic (40) Apoptosis (1) Bacterial (60) Beta-lactamase (4) Biochemical Assay Reagents (2) Cytochrome P450 (1) DNA/RNA Synthesis (2) Drug Derivative (2) Drug Metabolite (7) Fungal (1) Interleukin Related (1) Isotope-Labeled Compounds (2) NF-κB (1) p38 MAPK (1) PDI (1) Penicillin-binding protein (PBP) (14) Reference Standards (8)
By Research Areas:	Cancer (3) Cardiovascular Disease (3) Endocrinology (4) Infection (58) Inflammation/Immunology (8) Neurological Disease (1)
Oligonucleotides:	Adjuvant (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0958

Mupirocin 1 Publications Verification BRL-4910A; Pseudomonic acid	Bacterial Antibiotic Aminoacyl-tRNA Synthetase	Infection Endocrinology
Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .

HY-17593

Solithromycin 3 Publications Verification CEM-101; OP-1068	Bacterial Antibiotic	Infection
Solithromycin (CEM-101) is an orally bioavailable, effective antimicrobial agent, with IC₅₀s for inhibition of cell viability, protein synthesis, and growth rate are 7.5 ng/mL, 40 ng/mL, and 125 ng/mL for Streptococcus pneumonia, Staphylococcus aureus, and Haemophilus influenzae, respectively. Solithromycin binds to the large 50S subunit of the ribosome and inhibits protein biosynthesis .

HY-B0396

Tebipenem pivoxil L084	Penicillin-binding protein (PBP) Bacterial Antibiotic	Infection
Tebipenem pivoxil (L084) is an orally active antibiotic against a variety of pathogenic bacteria. Tebipenem pivoxil binds penicillin-binding protein (PBP), thereby inhibiting cell wall synthesis .

HY-B1228

Ribostamycin sulfate 1 Publications Verification Vistamycin sulfate	Antibiotic PDI	Infection
Ribostamycin sulfate (Vistamycin sulfate) is a broad-spectrum aminoglycoside Antibiotic with bactericidal activity against Gram-positive cocci, Gram-negative cocci, bacilli, and drug-resistant strains. Ribostamycin sulfate also acts as an inhibitor of protein disulfide isomerase (PDI), with a binding constant K_D of 319 μM for bovine PDI. Ribostamycin sulfate targets bacterial 16S ribosomal RNA and the 30S ribosomal subunit, causing translational misreading and thereby inhibiting bacterial protein synthesis. Ribostamycin sulfate disrupts the integrity of bacterial cell membranes, induces membrane pore formation, and leads to bacterial death. Ribostamycin sulfate can be used in studies related to bacterial infections .

HY-116815

Lalistat 1 2 Publications Verification	Beta-lactamase Bacterial	Infection Neurological Disease
Lalistat 1 is a potent, selective, and competitive inhibitor of lysosomal acid lipase (LAL) and against purified human LAL (phLAL) with an IC₅₀ of 68 nM. Lalistat 1 is a inhibitor of immunoglobulin A1 protease (IgA1P) proteases for H. influenzae, has less effects on other serine hydrolases (trypsin or β-lactamase, etc.). Lalistat 1 can be used for the research of niemann-pick type C (NPC) disease .

HY-B1325

Cefuroxime axetil	Bacterial Antibiotic	Infection Inflammation/Immunology
Cefuroxime axetil is an orally effective broad-spectrum β-lactam antibiotic that targets bacterial penicillin-binding proteins (PBPs, such as PBP3 and PBP1). Cefuroxime axetil inhibits cell wall synthesis, leading to bacterial lysis and death, with a minimum inhibitory concentration (MIC) of 0.12-4 mg/L for non-typeable Haemophilus influenzae (NTHi). Cefuroxime axetil is hydrolyzed by esterase to the active ingredient Cefuroxime (HY-B1256A) after oral absorption. Topical administration of Cefuroxime via bioadhesive nanoparticles (BNPs) can prolong the drug's retention time in the middle ear (≥7 days). Cefuroxime axetil can be used in the study of otitis media (especially NTHi infection). Cefuroxime axetil can achieve precise antibacterial effects through oral or topical nano-delivery systems, reducing systemic exposure and the risk of antibiotic resistance .

HY-19892A

Brilacidin tetrahydrochloride 1 Publications Verification PMX 30063 tetrahydrochloride	Bacterial Antibiotic	Infection Cancer
Brilacidin tetrahydrochloride (PMX 30063 tetrahydrochloride) is an anti-infective antimicrobial with MIC90s of 1 and 8 μg/mL for Gram-positive bacteria Streptococcus pneumonia and Streptococcus viridans, and MIC90 of 8 and 4 μg/mL for Gram-negative bacteria Haemophilus influenza and Pseudomonas aeruginosa. Brilacidin tetrahydrochloride is a defensin mimetic antibiotic compound .

HY-121329

Carumonam AMA-1080; Ro 17-2301	Penicillin-binding protein (PBP) Antibiotic Bacterial	Infection
Carumonam (AMA-1080; Ro 17-2301) is a sulfonated monocyclic β-Lactam Antibiotic, targeting to penicillin-binding protein (PBP). Carumonam exerts highly activity against Enterobacteriaceae, Pseudomonas aeruginosa, and Haemophilus influenzae, while it weakly and even inactively inhibits Streptococcus pneumoniae and Staphylococcus aureus. Carumonam is resistant to beta-lactamase-mediated hydrolysis .

HY-B0435

Roxithromycin Maximum Cited Publications 7 Publications Verification RU-28965	Bacterial Antibiotic Apoptosis p38 MAPK NF-κB	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Roxithromycin (RU-28965) is an orally active semi-synthethic macrolide antibiotic. Roxithromycin inhibits protein biosynthesis in the elongation step by binding to 50S bacterial ribosome. Roxithromycin has antimicrobial, antiproliferative, anti-inflammatory, tumour vasculature inhibiting and lung injury ameliorating effects .

HY-A0111

Cefetamet 1 Publications Verification Ro 15-8074; Deacetoxycefotaxime	Antibiotic Bacterial Penicillin-binding protein (PBP) Drug Metabolite	Infection
Cefetamet (Ro 15-8074) is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet kills and lyses Treponema pallidum. Cefetamet can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

HY-W108875

Mupirocin lithium 1 Publications Verification BRL-4910A lithium; Pseudomonic acid lithium	Antibiotic Bacterial Aminoacyl-tRNA Synthetase	Infection Endocrinology
Mupirocin lithium is an antibiotic. Mupirocin lithium inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin lithium has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin lithium can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .

HY-N7101

Cefpodoxime Proxetil U-76,252; CS-807	Bacterial Antibiotic Penicillin-binding protein (PBP)	Infection
Cefpodoxime Proxetil is an orally active broad spectrum third-generation cephalosporin with potent antibacterial activity against both Gram-positive and Gram-negative bacteria including staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pnuemoniae, Citrobacter spp, and Proteus spp. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis. Cefpodoxime Proxetil can be used against skin structure infections, acute otitis media, pharyngitis, tonsillitis, upper respiratory tract infection, urinary tract infections and sexually transmitted diseases .

HY-159688

Cefditoren 1 Publications Verification	Antibiotic Bacterial Penicillin-binding protein (PBP) Interleukin Related	Infection
Cefditoren is a broad-spectrum oral active cephalosporin that acts as a penicillin-binding protein (PBP) inhibitor. Cefditoren binds to specific PBPs in Gram-positive and Gram-negative bacteria, thereby inhibiting cell wall synthesis. Cefditoren also reduces serum levels of the inflammatory biomarkers IL-6 and KL-6. Cefditoren can be used in research related to acute exacerbation of chronic bronchitis, pharyngitis-tonsillitis, uncomplicated skin and skin structure infections, respiratory tract infections, acute pyelonephritis, and enterococcal endocarditis .

HY-10004

Faropenem daloxate Faropenem medoxil	Antibiotic Bacterial	Infection
Faropenem daloxate (Faropenem medoxil) is an orally active beta-lactam antibiotic. Faropenem daloxate has excellent in vitro activity against Streptococcus pneumonia, Haemophilus influenza, and other key pathogens implicated in acute bacterial rhino sinusitis. Faropenem daloxate can be studied in research for respiratory pathogens and acute bacterial sinusitis .

HY-14956

Nemonoxacin 1 Publications Verification TG-873870	Antibiotic Bacterial	Infection Inflammation/Immunology
Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .

HY-135221

Cefcapene pivoxil hydrochloride	Bacterial Antibiotic	Infection
Cefcapene pivoxil hydrochloride, the pivalate ester prodrug form of Cefcapene, is an orally active third-generation cephalosporin with a wide spectrum of anti-bacterial activity. Cefcapene pivoxil hydrochloride has the potential for the palmoplantar pustulosis (PPP) research .

HY-B1149A

Bacampicillin (hydrochloride)	Drug Derivative Bacterial	Infection
Bacampicillin hydrochloride is an orally active semi-synthetic aminopenicillin derivative, prodrug and bactericide that is readily inactivated by β-lactamases. Bacampicillin hydrochloride is hydrolyzed by carboxylester hydrolases and non-specific esterases in the gastrointestinal wall and plasma to form Ampicillin (HY-B0522), and produces higher levels of Ampicillin in rodents in vivo. Bacampicillin hydrochloride exhibits bactericidal activity against Gram-positive and Gram-negative bacteria. Bacampicillin hydrochloride can be used in studies related to bacterial infections .

HY-157363

Tryptone Soya Agar	Biochemical Assay Reagents	Others
Tryptone Soya Agar is a general-purpose culture medium for the isolation and cultivation of fastidious and non-fastidious microorganisms or the maintenance of stock culture.

HY-126463

LolCDE-IN-4	Bacterial	Infection
LolCDE-IN-4 (Compound 1) is exhibits antibacterial efficacy against gram negative bacteria Escherichia coli (MIC of 0.25-32 µg/ml) and Haemophilus influenzae, through inhibition LolCDE complex and disruption of lipoproteins release from the inner membrane .

HY-159687

Nafithromycin WCK 4873	Antibiotic Bacterial	Infection
Nafithromycin (WCK 4873) is an orally available antibiotic that inhibits community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Methicillin (HY-121544)-susceptible Staphylococcus aureus. The MIC₉₀ of nafithromycin against macrolide-resistant and telithromycin (HY-A0062)-insensitive Streptococcus pneumoniae is 0.12 mg/liter .

HY-U00380

Tigemonam	Antibiotic Beta-lactamase Bacterial	Infection
Tigemonam is an orally active monobactam antibiotic with a K_i of 0.86 μM against Enterobacter cloacae P99 β-lactamase and 50.8 μM against Escherichia coli TEM-1 β-lactamase. Tigemonam binds to penicillin-binding proteins 1a, 3, and 4, inhibits bacterial cell wall synthesis, and exhibits bactericidal activity against aerobic gram-negative bacteria including Enterobacteriaceae, Haemophilus influenzae, and Neisseria gonorrhoeae. Tigemonam resists hydrolysis by multiple β-lactamase enzymes, reduces bacterial load in systemic, pyelonephritic, lung, and thigh muscle infections in rodents, and shows minimal difference between minimum inhibitory and bactericidal concentrations. Tigemonam can be used for the research of gram-negative bacterial infections, acute pyelonephritis, lung infection, and thigh muscle infection .

HY-19892

Brilacidin PMX 30063	Bacterial Antibiotic	Infection Cancer
Brilacidin (PMX 30063) is an anti-infective antimicrobial with MIC90s of 1 and 8 μg/mL for Gram-positive bacteria Streptococcus pneumonia and Streptococcus viridans, and MIC90 of 8 and 4 μg/mL for Gram-negative bacteria Haemophilus influenza and Pseudomonas aeruginosa. Brilacidin is a defensin mimetic antibiotic compound .

HY-159746

Carbomer adjuvant (HS801)	Biochemical Assay Reagents	Inflammation/Immunology
Carbomer adjuvant (HS801) is an adjuvant composed of carbomer and cationic polymers. This adjuvant is safe, non-toxic, and metabolizable. It can enhance the immune response, increase the antibody titer of each antigen component of the vaccine after immunization, and reduce the number of immunizations required. It is suitable for various veterinary vaccines. It is recommended for use in porcine circovirus, mycoplasma hyopneumoniae, and haemophilus parasuis.

HY-14956S

Nemonoxacin-d3 TG-873870-d₃	Bacterial	Inflammation/Immunology
Nemonoxacin-d₃ is the deuterium labeled Nemonoxacin. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .

HY-145158

Temocillin	Bacterial Antibiotic Drug Derivative Beta-lactamase	Infection
Temocillin is a derivative of Ticarcillin (HY-100577) and a β-lactamase-resistant Antibiotic. Temocillin blocks water molecules from entering the active sites of Ambler class A and class C serine-dependent β-lactamases, resisting hydrolysis by these enzymes. Temocillin exhibits antibacterial activity against Enterobacteriaceae and Neisseria gonorrhoeae. Temocillin shows antagonistic effects against some isolated strains when used in combination with Ticarcillin (HY-100577) or Cefazolin (HY-B1892). Temocillin can be used in research related to sepsis, urinary tract infections, and lower respiratory tract infections .

HY-W023253

Biclotymol	Bacterial Fungal	Infection Inflammation/Immunology
Biclotymol is an antimicrobial agent against gram-positive cocci. Biclotymol inhibits Streptococcus pneumoniae and Haemophilus influenzae, with MIC of 150 and 150 μM. Biclotymol exhibits anti-inflammatory and analgesic activity and ameliorates the otolaryngology infection and throat sore .

HY-19428A

Ranbezolid hydrochloride RBx-7644	Antibiotic Bacterial	Infection Cardiovascular Disease
Ranbezolid (RBx7644 free base) is an orally active, oxazolidinone antibiotic against Gram-positive and Gram-negative anaerobes including Staphylococcus aureus, Staphylococcus epidermidis and Bacteroides fragilis. Ranbezolid can inhibit the 50s ribosomal subunit with an IC₅₀ of 17 μM for bacterial ribosomes. Ranbezolid interferes cell wall and lipid synthesis. Ranbezolid can rapidly kill bacteria, significantly reduce bacterial load, and has better cardiovascular safety. Ranbezolid can be used for the study of antibiotics for anaerobic bacteria .

HY-19428

Ranbezolid RBx7644 free base	Antibiotic Bacterial	Infection Cardiovascular Disease
Ranbezolid (RBx7644 free base) is an orally active, oxazolidinone antibiotic against Gram-positive and Gram-negative anaerobes including Staphylococcus aureus, Staphylococcus epidermidis and Bacteroides fragilis. Ranbezolid can inhibit the 50s ribosomal subunit with an IC₅₀ of 17 μM for bacterial ribosomes. Ranbezolid interferes cell wall and lipid synthesis. Ranbezolid can rapidly kill bacteria, significantly reduce bacterial load, and has better cardiovascular safety. Ranbezolid can be used for the study of antibiotics for anaerobic bacteria .

HY-B0396A

Tebipenem pivoxil hydrochloride L084 hydrochloride	Penicillin-binding protein (PBP) Bacterial Antibiotic	Infection
Tebipenem pivoxil (L084) hydrochloride is an orally active antibiotic against a variety of pathogenic bacteria. Tebipenem pivoxil hydrochloride binds penicillin-binding protein (PBP), thereby inhibiting cell wall synthesis .

HY-W743473

Cefetamet-d3 Ro 15-8074-d₃; Deacetoxycefotaxime-d₃	Isotope-Labeled Compounds Bacterial Antibiotic Penicillin-binding protein (PBP) Drug Metabolite	Infection
Cefetamet-d₃ (Ro 15-8074-d₃; Deacetoxycefotaxime-d₃) is the deuterium labeled Cefetamet (HY-A0111). Cefetamet (Ro 15-8074) is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet kills and lyses Treponema pallidum. Cefetamet can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

HY-121195

Apalcillin PC-904	Bacterial	Infection
Apalcillin (PC-904) in combination with Ro 48-1220, a penam sulfone β-lactamase inhibitor, demonstrated broad-spectrum activity against gram-negative aerobic and anaerobic bacteria, excluding Klebsiella oxytoca. It exhibited potent activity against β-lactamase-producing Moraxella catarrhalis, Haemophilus influenzae, and Neisseria gonorrhoeae, with effective MICs (11 μg/mL). The combination also inhibited Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter species at low MICs (0.25 to 4 μg/mL). However, its efficacy against oxacillin-resistant staphylococci and certain gram-positive organisms was limited. Apalcillin/Ro 48-1220 showed comparable efficacy to piperacillin/tazobactam against some extended-spectrum β-lactamase-producing Escherichia coli but was less effective against SHV-type β-lactamases .

HY-105213

YM-17K MC-352	Antibiotic Bacterial	Infection
YM-17K (MC-352) is a macrolide antibiotic. YM-17K exhibits antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, and anaerobic bacteria. YM-17K exhibits stable activity in serum and is less affected by pH values .

HY-111127

LY164846	Antibiotic Bacterial	Infection
LY164846 is an orally active cephalosporin. LY164846 is highly sensitive to Haemophilus influenzae (including Ampicillin (HY-B0522)-resistant strains) and Moraxella catarrhalis (with MIC₉₀ ≤ 4 μg/mL). LY164846 is generally sensitive to Methicillin (HY-121544)-resistant Staphylococcus aureus and Streptococcus (except Enterococcus) (with MIC₉₀: 0.25 - 8 μg/mL), and moderately sensitive to anaerobic bacteria. LY164846 has MBC/MIC ratio to Haemophilus influenzae of ≤ 2, showing bactericidal activity. LY164846 can be used for research on respiratory and skin infections .

HY-161788

DNA Gyrase-IN-11	DNA/RNA Synthesis Bacterial	Infection
DNA Gyrase-IN-11 (Compound 23Be) is an inhibitor for protein synthesis (IC₅₀ is 0.74 μM) and DNA replication. DNA Gyrase-IN-11 inhibits DNA gyrase, that inhibits E. coli DNA supercoiling with IC₅₀ of 11.9 μM. DNA Gyrase-IN-11 exhibits antibacterial efficacy, that inhibits Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Staphylococcus aureus, with MICs of 0.008-0.25 μg/mL .

HY-120583A

LY 255262	Bacterial	Infection
LY 255262 is an antibacterial agent. LY 255262 exhibits potent inhibitory effects against a variety of Gram-positive and Gram-negative bacteria in vitro. LY 255262 has MIC values of 64, 0.25, 0.5, 0.25, 0.25, 1, and 1 μg/mL for Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenza, Escherichia coli, Klebsiella, Enterobacter aerogenes, and Serratia, respectively. LY 255262 has a relatively weak inhibitory effect on Pseudomonas (MIC >128 μg/mL). LY 255262 can be used in antibacterial research .

HY-W747311

Ritipenem	Antibiotic Bacterial Penicillin-binding protein (PBP)	Infection
Ritipenem is a penicillin antibiotic, that targets penicillin-binding protein with good affinity (IC₅₀ in levels of ng/mL), and exhibits antibacterial properties. Ritipenem exhibits antiviral activity against Haemophilus influenzae .

HY-W744633

Cefdaloxime	Drug Metabolite Bacterial	Infection
Cefdaloxime is an orally active cephalosporin and HR-916 ester metabolite. Cefdaloxime has a broad spectrum of activity against pathogens such as the majority of members of the family Enterobacteriaceae, staphylococci, Streptococcus spp., Neisseria gonorrhoeae, Moraxella catarrhalis, Haemophilus influenzae .

HY-N14906

4-Diazo-3-methoxy-2,5-cyclohexadien-1-one	Bacterial	Infection
4-Diazo-3-methoxy-2,5-cyclohexadien-1-one has favourable anti-anaerobe activity. MIC: 0.4 μg/mL for Clostridium and Bacterioids, 0.2 μg/mL for Haemophilus .

HY-14956S1

Nemonoxacin-d3-1 TG-873870-d₃-1	Bacterial	Inflammation/Immunology
Nemonoxacin-d₃-1 is the deuterium labeled Nemonoxacin. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .

HY-14956S2

Nemonoxacin-d4 TG-873870-d₄	Bacterial	Inflammation/Immunology
Nemonoxacin-d₄ is the deuterium labeled Nemonoxacin. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .

HY-123508

PD 131628	Drug Metabolite Bacterial	Infection
PD 131628 is an antimicrobial agent and active PD 131112 metabolite. PD 131628 is two- to four-fold more active than Ciprofloxacin (HY-B0356), inhibiting all strains of Staphylococcus aureus and Streptococcus pneumoniae. PD 131628 is very active against Neisseria spp., Haemophilus influenzae and Moraxella catarrhalis, with MIC₉₀s ranging from 0.004 to 0.008 mg/L .

HY-135221R

Cefcapene pivoxil hydrochloride (Standard)	Reference Standards Bacterial Antibiotic	Infection
Chenodeoxycholic Acid (Standard) is the analytical standard of Chenodeoxycholic Acid. This product is intended for research and analytical applications. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-17593R

Solithromycin (Standard) CEM-101 (Standard); OP-1068 (Standard)	Reference Standards Bacterial Antibiotic	Infection
Solithromycin (Standard) is the analytical standard of Solithromycin. This product is intended for research and analytical applications. Solithromycin (CEM-101) is an orally bioavailable, effective antimicrobial agent, with IC₅₀s for inhibition of cell viability, protein synthesis, and growth rate are 7.5 ng/mL, 40 ng/mL, and 125 ng/mL for Streptococcus pneumonia, Staphylococcus aureus, and Haemophilus influenzae, respectively. Solithromycin binds to the large 50S subunit of the ribosome and inhibits protein biosynthesis .

HY-B0958R

Mupirocin (Standard) BRL-4910A (Standard); Pseudomonic acid (Standard)	Reference Standards Bacterial Antibiotic Aminoacyl-tRNA Synthetase	Infection Endocrinology
Mupirocin (Standard) is the analytical standard of Mupirocin (HY-B0958). This product is intended for research and analytical applications. Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .

HY-10004R

Faropenem daloxate (Standard) Faropenem medoxil (Standard)	Reference Standards Antibiotic Bacterial	Infection
Faropenem daloxate (Faropenem medoxil) (Standard) is the analytical standard of Faropenem daloxate (Faropenem medoxil). This product is intended for research and analytical applications. Faropenem daloxate is an orally active beta-lactam antibiotic. Faropenem daloxate has excellent in vitro activity against Streptococcus pneumonia, Haemophilus influenza, and other key pathogens implicated in acute bacterial rhino sinusitis. Faropenem daloxate can be studied in research for respiratory pathogens and acute bacterial sinusitis .

HY-125579

Ro 25-0534	Bacterial	Infection
Ro 25-0534 is an antimicrobial compound against Pseudomonas. Ro 25-0534 is active against Enterobacteriaceae (MIC₉₀: 0.06-2 μg/mL), Oxacillin (HY-B0465)-susceptible staphylococci, β-hemolytic streptococci, and penicillin-susceptible pneumococci (MIC₉₀: 1-2 μg/mL), Haemophilus influenzae (MIC₉₀: 0.25-0.5 μg/mL), Moraxella catarrhalis (MIC₉₀: 0.5 μg/mL), and most nonenteric Gram-negative bacilli (MIC₉₀: 2-4 μg/mL) .

HY-W108875R

Mupirocin lithium (Standard) BRL-4910A lithium (Standard); Pseudomonic acid lithium (Standard)	Antibiotic Bacterial Reference Standards Aminoacyl-tRNA Synthetase	Infection Endocrinology
Mupirocin (lithium) (Standard) is the analytical standard of Mupirocin lithium (HY-W108875). This product is intended for research and analytical applications. Mupirocin lithium is an antibiotic. Mupirocin lithium inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin lithium has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin lithium can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .

HY-A0111A

Cefetamet sodium Ro15-8074/001; Deacetoxycefotaxime sodium	Antibiotic Bacterial Penicillin-binding protein (PBP) Drug Metabolite	Infection
Cefetamet (Ro 15-8074) sodium is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet sodium binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet sodium has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet sodium kills and lyses Treponema pallidum. Cefetamet sodium can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

HY-A0111B

Cefetamet hydrochloride Ro 15-8074 hydrochloride; Deacetoxycefotaxime hydrochloride	Antibiotic Bacterial Penicillin-binding protein (PBP) Drug Metabolite	Infection
Cefetamet (Ro 15-8074) hydrochloride is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet hydrochloride binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet hydrochloride has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet hydrochloride kills and lyses Treponema pallidum. Cefetamet hydrochloride can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

HY-B1894

Cefetamet pivoxyl Ro 15-8075 free base	Antibiotic Bacterial	Infection
Cefetamet pivoxyl (Ro 15-8075 free base) is an orally active cephalosporin Antibiotic and a prodrug of Cefetamet (HY-A0111). After ingestion, Cefetamet pivoxyl is hydrolyzed by gastrointestinal esterases to form Cefetamet. Cefetamet pivoxyl is primarily active against aerobic Gram-negative bacteria (such as Enterobacteriaceae, Neisseria, Haemophilus) and some Gram-positive bacteria (such as non-enterococcal streptococci). Cefetamet pivoxyl exhibits potent in vivo antibacterial activity against strains of Gram-positive bacteria (S. pyogenes) and Gram-negative bacteria (E. coli, K. pneumoniae, S. marcescens, P. vulgaris, P. mirabilis, H. influenzae) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0958

Mupirocin 1 Publications Verification BRL-4910A; Pseudomonic acid	Infection Microorganisms Classification of Application Fields Antibiotics Antibacterial Disease Research Disease Research Fields Other Antibiotics Source Classification	Bacterial Antibiotic Aminoacyl-tRNA Synthetase
Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .

HY-B1228

Ribostamycin sulfate 1 Publications Verification Vistamycin sulfate	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Resistance Selection Antibacterial Disease Research Disease Research Fields Other Antibiotics Source Classification	Antibiotic PDI
Ribostamycin sulfate (Vistamycin sulfate) is a broad-spectrum aminoglycoside Antibiotic with bactericidal activity against Gram-positive cocci, Gram-negative cocci, bacilli, and drug-resistant strains. Ribostamycin sulfate also acts as an inhibitor of protein disulfide isomerase (PDI), with a binding constant K_D of 319 μM for bovine PDI. Ribostamycin sulfate targets bacterial 16S ribosomal RNA and the 30S ribosomal subunit, causing translational misreading and thereby inhibiting bacterial protein synthesis. Ribostamycin sulfate disrupts the integrity of bacterial cell membranes, induces membrane pore formation, and leads to bacterial death. Ribostamycin sulfate can be used in studies related to bacterial infections .

HY-N14906

4-Diazo-3-methoxy-2,5-cyclohexadien-1-one	Natural Products Microorganisms Source Classification	Bacterial
4-Diazo-3-methoxy-2,5-cyclohexadien-1-one has favourable anti-anaerobe activity. MIC: 0.4 μg/mL for Clostridium and Bacterioids, 0.2 μg/mL for Haemophilus .

HY-B0958R

Mupirocin (Standard) BRL-4910A (Standard); Pseudomonic acid (Standard)	Structural Classification Microorganisms Antibiotics Antibacterial Disease Research Other Antibiotics Source Classification	Reference Standards Bacterial Antibiotic Aminoacyl-tRNA Synthetase
Mupirocin (Standard) is the analytical standard of Mupirocin (HY-B0958). This product is intended for research and analytical applications. Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .

Cat. No.	Product Name	Chemical Structure

HY-14956S

Nemonoxacin-d3

Nemonoxacin-d₃ is the deuterium labeled Nemonoxacin. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .

HY-W743473

Cefetamet-d3

Cefetamet-d₃ (Ro 15-8074-d₃; Deacetoxycefotaxime-d₃) is the deuterium labeled Cefetamet (HY-A0111). Cefetamet (Ro 15-8074) is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet kills and lyses Treponema pallidum. Cefetamet can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

HY-14956S1

Nemonoxacin-d3-1

Nemonoxacin-d₃-1 is the deuterium labeled Nemonoxacin. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .

HY-14956S2

Nemonoxacin-d4

Nemonoxacin-d₄ is the deuterium labeled Nemonoxacin. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .

HY-N7101S

Cefpodoxime proxetil-d7

Cefpodoxime proxetil-d7 (U-76-d7,252-d7; CS-807-d7) is the deuterium labeled Cefpodoxime Proxetil (HY-N7101). Cefpodoxime Proxetil is an orally active broad spectrum third-generation cephalosporin with potent antibacterial activity against both Gram-positive and Gram-negative bacteria including staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pnuemoniae, Citrobacter spp, and Proteus spp. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis. Cefpodoxime Proxetil can be used against skin structure infections, acute otitis media, pharyngitis, tonsillitis, upper respiratory tract infection, urinary tract infections and sexually transmitted diseases .

Cat. No.	Product Name		Classification

HY-159746

Carbomer adjuvant (HS801)		Adjuvant
Carbomer adjuvant (HS801) is an adjuvant composed of carbomer and cationic polymers. This adjuvant is safe, non-toxic, and metabolizable. It can enhance the immune response, increase the antibody titer of each antigen component of the vaccine after immunization, and reduce the number of immunizations required. It is suitable for various veterinary vaccines. It is recommended for use in porcine circovirus, mycoplasma hyopneumoniae, and haemophilus parasuis.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks